Amgen is seeking approval for an additional indication in glucocorticoid-induced osteoporosis for its blockbuster osteoporosis therapeutic, Prolia.
FDA has accepted for review a supplemental biologics license application (sBLA) filed by Amgen for its osteoporosis drug, Prolia (denosumab), seeking approval for treating glucocorticoid-induced osteoporosis (GIOP), Amgen announced on Oct. 9, 2017. Prolia, approved by FDA in 2010, is among Amgen’s top-selling products with 2016 sales of more than $1.6 billion.
The sBLA was submitted on July 28, 2017, and FDA has set a Prescription Drug User Fee Act action date of May 28, 2018. GIOP is the most common form of secondary osteoporosis.
"We believe that Prolia can address a critical treatment need for patients with glucocorticoid-induced osteoporosis, which is the most common drug-induced form of the disease," said Sean E. Harper, MD, executive vice president of Research and Development at Amgen, in a company press release. "We will continue to work closely with [FDA] as they review our application and look forward to expanding Prolia's benefits to patients with this serious condition that is often underestimated and untreated."
Prolia is indicated for treating osteoporosis in postmenopausal women. It is also indicated for increasing bone mass in men with osteoporosis at high risk for fracture and for increasing bone mass in women undergoing breast cancer treatment who are at high risk for fracture.
Source: Amgen
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.